Transcription factors are known to interact with each other to modulate their transcriptional activity. In this study, we found that the transcriptional activity of human Erg (one of the Ets family-transcription factors) was repressed by several nuclear receptors, including human estrogen receptor ERa, nonsteroid receptors and orphan receptors. Conversely, Erg inhibited ERa-dependent transcription. These reciprocal functional interactions extended to other nuclear receptors such as thyroid hormone and retinoic acid receptors, as well as to Fli1, an ERG-related ETS factor. Although similarly inhibited by overexpression of the orphan nuclear receptors ERR1 and RORa, ERG activity was unaffected by either REVERBa1 or COUP-TFII. The antagonism between ERG and ERa did not depend on DNA binding inhibition or direct protein-protein interactions. Repression of ERadependent transcription required the carboxyterminal and aminoterminal transactivation domains of Erg whereas the carboxyterminal AF-2 domain of ERa was necessary for repression of Erg activity. Reciprocal inhibition between Erg and ERa was not alleviated by overexpressing CBP, SRC-1 or RIP 140, three nuclear coactivator proteins. A negative cross-talk observed between Erg and ERa expands their potential range of regulation and may be relevant in vivo, particularly in endothelial, urogenital and cartilaginous tissues where both factors are expressed.
Introduction
ETS genes encode eukaryotic transcription factors that share a unique highly conserved DNA-binding domain of 85 amino acids called the ETS domain (Graves and Petersen, 1998) . It controls DNA interaction and allows recognition of a unique purine-rich sequence motif, the ETS binding site (EBS), centered on the core sequence, 5
0 -GGAA/T-3 0 (Sharrocks et al., 1997) . ERG and FLI1 belong to the ERG group and, besides the ETS domain, share an additional conserved domain in their aminoterminal part called the pointed domain (PNT) (Rao et al., 1987) . Other proteins in the family such as ETS1, ETS2, GABPa, TEL and YAN also share the PNT domain (Graves and Petersen, 1998) . ETS proteins are found in animals across the phylogenetic spectrum, from flies and worms to man, with over 20 homologues in the human genome . They are therefore believed to hold a key role in regulating cellular proliferation and differentiation during embryonic development, as well as in adults. They may control the expression of several target genes including transcription factor genes, immune response genes and genes encoding matrix-degrading proteases, growth factors or their receptors (Crepieux et al., 1994; Sharrocks et al., 1997) . In addition to regulating the development and function of a number of cell lineages, several ETS proteins, including ETS1, ETS2, PU.1, FLI1, ERG and TEL, display oncogenic potential (Dittmer and Nordheim, 1998) . For example, the deregulation of many ETS proteins such as FLI1 or ERG by chromosomal translocation leads to Ewing's sarcoma or acute myeloid leukemia in humans (Delattre et al., 1992; Shimizu et al., 1993; Zucman et al., 1993) .
Members of the nuclear receptor family bind with a wide range of ligands, including steroid hormones such as estrogens (ER, NR3A in the official nomenclature (Committee Nuclear Receptor Nomenclature, 1999)), glucocorticoids (GR, NR3C1) and androgens (AR, NR3C1), and nonsteroid ligands such as thyroid hormones (TR, NR1A), retinoic acid (RAR, NR1B; RXR, NR2B), vitamin D (VDR, NR1I), as well as diverse products of lipid metabolism (PPARs, NR1C) (Gronemeyer and Laudet, 1995; Mangelsdorf et al., 1995) . The nuclear receptor superfamily also includes a large number of so-called orphan receptors for which regulatory ligands have not been identified or may not exist (Enmark and Gustafsson, 1996) . Nuclear receptors act as ligand-inducible transcription factors that activate or repress target genes by binding directly to specific DNA hormone-response elements (HRE) (Mangelsdorf et al., 1995) . By binding as homodimers or heterodimers to these cognate DNA elements, they interact, either directly or via protein partners, with the basal transcrip-tion complex, and in so doing alter the transcription rates of hormone-sensitive genes. Consequently they regulate diverse aspects of growth, development and homeostasis. While the ligands for nuclear receptors are diverse, the receptors themselves are highly conserved and share a modular structure consisting grossly of three separable domains (Gronemeyer and Laudet, 1995; Mangelsdorf et al., 1995) . The central domain is a highly evolutionary conserved DNA-binding domain containing two zinc-finger motifs. The aminoterminal domain is poorly conserved and contains, at least in some nuclear receptors, an autonomous activation function (ligand-independent AF-1). The variable carboxyterminal domain binds the ligand and confers ligand-specific and ligand-dependent transcriptional activities (AF-2) to nuclear receptors. Recent studies indicate that the transcriptional activity of nuclear receptors also depends on a class of proteins collectively referred to as coactivators, including members of the p160 coactivator family, such as SRC1 and GRIP1/ TIF2 and members of the CBP/p300 family (Robyr et al., 2000) . These proteins are believed to bridge the nuclear receptors to the RNA polymerase II transcription machinery. Some of them, such as the p160 coactivators, are structurally related proteins that mediate the activity of the ligand-dependent AF-2 (Robyr et al., 2000) .
ETS factors and nuclear receptors belong to the two main signaling systems used by the cell to receive extracellular signals. The first includes membrane receptors that transmit activation signals to nuclear transcription factors such as ETS factors via protein kinase cascades (Wasylyk et al., 1998) . The second system involves nuclear receptors that regulate gene expression by themselves in a ligand-dependent manner (Mangelsdorf et al., 1995) . It seems there is a general regulatory switch that allows cross-talk between both signaling systems, as best exemplified by the well-known cross-talk between nuclear receptors and the AP-1 complex (Pfahl, 1993) . The cross-talk may do the finetuning for the regulation of important biological processes such as cell differentiation and proliferation. Functional interactions have been reported between some ETS factors such as Spil/PU.1 (Gauthier et al., 1993) , ERM (Schneikert et al., 1996) , Flil (Darby et al., 1997) , PDEF (prostate-derived ETS factor) (Oettgen et al., 2000) , Gabpa (Aurrekoetxea-Hernandez and Buetti, 2000), ETS1 (Dwivedi et al., 2000; Tolon et al., 2000) , and ETS2 (Mullick et al., 2001) , and nuclear receptors. The first results showed that ETS factordependent transcription was inhibited by ligand-activated GR, AR, RARa (NR1B1) or TR (Gauthier et al., 1993; Schneikert et al., 1996; Darby et al., 1997) . Conversely, the activation of target genes by GR, TR, RARa or ERa(NR3A1) is repressed by several ETS factors (Gauthier et al., 1993; Schneikert et al., 1996; Darby et al., 1997) . Recently, cooperative interactions between AR, VDR or GR and ETS factors such as PDEF, Ets1 or Gabpa have been observed (Aurrekoetxea-Hernandez and Buetti, 2000; Dwivedi et al., 2000; Oettgen et al., 2000; Tolon et al., 2000; Mullick et al., 2001) . The mechanisms by which these reciprocal interactions occur remain to be determined. Also unknown is whether the cross-talk is shared by all ETS factors and nuclear receptors. In this study, we focused on human ERG and ERa proteins and demonstrated mutual repression of respective transactivation activities. This functional interaction was also observed with the ERG-related FLI1 factor and other nuclear receptors, including orphan receptors. The ERG domain responsible for repression of ER-dependent transcription has been delineated in the carboxyterminal and aminoterminal transactivation domains. Conversely, the carboxyterminal AF-2 domain of ER was involved in repressing ERG activity. Our results support the hypothesis of mutual repression by competition for a common coactivator protein.
Results

Mutual transcriptional interference between ERG and ERa
To study a possible link between the ETS-related factor ERG and ERa activities, we investigated whether ERG expression could affect ERa-induced transcription. As expected, ERa induced the activity of a reporter gene, ERE-LUC in ROS cells upon the addition of the agonist, that is, estradiol. As shown in Figure 1a , the cotransfection of an ERG-expression plasmid, pSG5-ERG, inhibited receptor activity when hormone was added and slightly when estradiol concentrations were minimized (charcoal-treated fetal calf serum). Repression depended on the amount of the transfected ERG expression vector. By contrast, transfection of parental plasmid pSG5, which lacks ERG coding sequences, did not alter the ER activition of ERE-LUC. We also checked that transfection of the ERG expression plasmid did not affect the basal activity of ERE-LUC in the absence of cotransfected ER expression plasmid (data not shown).
To investigate whether ERa antagonizes ERGmediated transcription, we used a reporter gene, Pye-LUC that contains ETS-responsive elements upstream of the luciferase gene (Wasylyk et al., 1989; Carre`re et al., 1998) . Its activity was efficiently induced by ERG in ROS cells. To determine whether the ERa is involved in repression of ERG activity by estradiol, the Pye-LUC reporter was transfected into ROS cells with ERGexpression vector and increasing amounts of an ERaexpression vector. As shown in Figure 1b , in ROS cells cultured with minimized estradiol concentrations, ERa inhibited ERG-induced reporter activity in a concentration-dependent manner. Transfection of the empty parental plasmid pSG5 only altered Pye-LUC activity to a similar extent as estradiol alone (Figure 1b) . ERamediated inhibition of reporter activity was stronger when culture medium was supplemented with hormone. By contrast, transfection of the ERa expression plasmid did not affect the basal activity of Pye-LUC in the absence of cotransfected ERG expression plasmid (data not shown). To determine whether the ERa repression activity against ERG shown in Figure 1b was promoterdependent or not, ROS cells were transfected with ERG and ERa expression plasmids together with the ERGsensitive (E74) 4 -LUC reporter plasmid. Cotransfection of ERa expression plasmid also resulted in repression of ERG transactivation of (E74) 4 -LUC reporter as was observed with the Pye-LUC reporter (data not shown). These results suggest that the mutual negative cross-talk is unlikely to be promoter-specific. Likewise, it did not appear to be cell-specific since similar results were obtained when transfection experiments were performed in COS cells (data not shown).
Mutual interference with ERG factor is shared by several members of the nuclear receptor family Since a mutual repression of transcription function was observed between ERG and ERa, it was interesting to see whether ERG and other nuclear receptors also engaged in similar interactions. The ERE-LUC reporter provided an opportunity to examine a potential ERGmediated inhibition of two nuclear receptors related to ERa: ERb (NR3A2), another estrogen receptor, and ERR1 (NR3B1), an orphan receptor. In ROS cells, cotransfections of increasing amounts of ERG expression plasmid inhibited ERb or ERR1-mediated reporter activity ( Figure 2a ). As expected, the control plasmid pSG5, lacking the ERG coding sequences, had no effect on ERb or ERR1 induction. Conversely, when Pye-LUC was cotransfected into ROS cells together with an ERb expression vector, we observed a clear reduction of ERG-induced reporter activity, stronger when estradiol was added ( Figure 2b ). As expected, the empty parental vector pSG5 had no effect. Cotransfection of an ERR1 expression vector also led to a reduction of ERG-induced Pye-LUC activity (Figure 2b ).
To determine whether the inhibitory effect produced by estrogen receptors could be extended to other nuclear receptors, we attempted to determine whether TRa1, TRb1, RARa and RXRa were able to inhibit ERGmediated activation of Pye-LUC reporter plasmid. In ROS cells, the presence of any of these four receptors strongly inhibited the activation, especially when they were bound to the corresponding ligand, whereas the control plasmids, lacking the coding sequences, had no effect on the cells (see for a representative example RXRa-induced inhibition of ERG-mediated transcription, Figure 3a) . Inhibition of ERG-induced reporter activity correlated positively with the concentration of the receptor expression vector and was stronger in the presence of the nuclear receptor-specific ligand. Conversely, transfection of ERG expression vector into ROS cells induced dose-dependent repression of the activation of a specific reporter plasmid by either liganded TRa1, TRb1, RARa or RXRa (in Figure 3b as an example). It has already been shown that FLI1, the closest ERG-related gene ETS factor (Ben-David and Bernstein, 1991) , could engage mutual repression of transcription function with RARa, TRa1 and GR (Darby et al., 1997) . We confirmed mutual interference between FLI1 and either RARa or TRa1 into ROS cells and also observed such interactions between FLI1 and ERa, TRb1 and RXRa (data not shown). In these experiments, FLI1 was as effective as ERG in inhibiting hormone-dependent nuclear receptor-mediated transcription.
Taken together, these results show that mutual repressive interactions with ERG factor are shared by Figure 1 Mutual repression of transcription between human ligand-activated ERa and ERG. (a) ROS cells were transfected with 1 mg of DNA including 200 ng of ER/ERR-sensitive ERE-LUC reporter plasmid and either empty expression plasmids, 100 ng of pSG5-ERa or increasing amounts of pSG5-ERG. Cells were harvested, and extracts were processed for LUC assays. LUC activity was measured and plotted as the percentage of change from basal activation (activation of the ERE-LUC reporter plasmid by ERa). Cells were cultured with minimized hormone concentrations (charcoal-treated fetal calf serum; black blocks) or with medium supplemented with estradiol (up to 10 À6 mM; white blocks). Presented is the average of at least three independent experiments. Data were plotted as the percentage of change from basal activation (activation of the ERE-LUC reporter plasmid by ERa). (b) ROS cells were transfected with 1 mg of DNA including 200 ng of ERG-sensitive Pye-LUC reporter plasmid and either empty expression plasmids, 100 ng of pSG5-ERG, or increasing amounts of pSG5-ERa as indicated. When added, estradiol concentration was 10 À6 M (white blocks). Data were plotted as the percentage of change from basal activation (activation of the PYE-LUC reporter plasmid by ERG)
Mutual repression between ERG and ER V Vlaeminck-Guillem et al ERa, ERa-related nuclear receptors such as ERb and ERR1, and also by nonsteroid nuclear receptors.
The ERG-dependent transcription is differentially repressed by orphan receptors
Numerous members of the nuclear receptor family have been identified for which there are no apparent ligands. Some of these so-called orphan receptors may interact with novel ligands, while others may represent constitutive repressors (Enmark and Gustafsson, 1996) . The results described above show that the orphan receptor ERR1 is able to repress ERG-dependent transcription. Therefore we also tested if other orphan receptors behave similarly. To do so, we cotransfected the ERGsensitive Pye-LUC reporter plasmid in ROS cells together with an ERG expression plasmid and increasing amounts of expression plasmids for either REVERBa (NR1D1), RORa1 (NR1F1) or COUP-TFII (NR2F1). As shown in Figure 4a , activation of the Pye-LUC reporter plasmid fell as increasing amounts of RORa1 expression plasmids were included in the transfection. By contrast, the repressors REV-ERBa and COUP-TFII had no ability to repress ERG transcriptional activity and even appeared to induce a dose-dependent increase in the activity of the reporter plasmid (Figure 4b and c). Thus some orphan receptors differentially interfere with ERGdependent transcription. (a) ROS cells were transfected with 1 mg of DNA including 100 ng of RXRa-sensitive DR1-CAT reporter plasmid and either empty expression plasmids, 300 ng of pCMX-RXRa or increasing amounts of pSG5-ERG. Cells were cultured with minimized hormone concentrations (charcoal-treated fetal calf serum; black blocks) or with medium supplemented with 9-cis retinoic acid (up to 10 À8 M; white blocks). CAT activity was measured and plotted as the percentage of change from basal activation (activation of the DR1-CAT reporter plasmid by RXRa). Presented is the average of at least three independent experiments. (b) ROS cells were transfected with 1 mg of DNA including 200 ng of ERG-sensitive Pye-LUC reporter plasmid and either empty expression plasmids, 100 ng of pSG5-ERG or increasing amounts of pCMX-RXRa as indicated. 9-cis retinoic acid (RA) (10 À8 M) was added to the appropriate plates (white blocks). Data were plotted as the percentage of change from basal activation (activation of the Pye-LUC reporter plasmid by ERG).
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Mutual interference between ERG and ERa does not result from reciprocal inhibition of DNA binding To investigate the mechanism by which ERG and ERa interact functionally with each other, we first examined the hypothesis that ERa can interfere with ERG activity by binding to the ERG binding site, thereby repressing ERG activity by a simple competitive DNA-binding mechanism. Gel retardation experiments were carried out with an ETS consensus binding site (EBS) DNA fragment. As shown in Figure 5 , specific binding of cellfree translated ERG to this fragment was readily detected (lane 2) and was competed with a 50-fold excess of unlabelled EBS fragment (lane 5). No significant binding of ERa to EBS could be observed with or without estradiol (lanes 7-8), although the same amount of ERa exhibited easily detectable binding to an ERE. Conversely, gel retardation experiments failed to demonstrate any significant binding of ERG to a DNA fragment surrounding an ERE while ERa was found to bind it efficiently (data not shown).
As a possible explanation for the ability of ERa to repress ERG activity, we examined its effect on ERG binding activity. When cell-free translated ERa protein was incubated (lane 3) with in vitro translated ERG, no significant inhibition of ERG binding to the EBS was observed. The ERG-EBS complex also remained unaffected by ERa incubation in the presence of estradiol (lane 4). Conversely, incubation of ERa with Figure 4 RORa1, REV-ERBa and COUP-TF2 orphan receptors differentially interfere with ERG activity. ROS cells were transfected with 1 mg of DNA including 200 ng of ERG sensitive Pye-LUC reporter plasmid and either empty expression plasmids, 100 ng of pSG5-ERG or increasing amounts of pSG5-RORa1 (a), REV-ERBa (b) or COUP-TF2 (c) as indicated. Presented is the average of at least three independent experiments. Data were plotted as the percentage of change from basal activation (activation of the Pye-LUC reporter plasmid by ERG) Figure 5 Mutual interference between ERG and ERa does not result from mutual inhibition of DNA binding. Complexes formed between 32 P-labeled ETS binding site (EBS) DNA probe and cellfree translated proteins were analysed by electrophoretic mobility shift assays. Reactions were simultaneously incubated with or without the purified full-length ERa. Estradiol was added prior to the DNA-binding assays when indicated. The ERG-EBS complex is indicated by an arrow. Lane 1 shows the mobility of the unbound 32 P-labeled EBS probe in the absence of any added protein 
Mutual interference does not result from direct proteinprotein interaction
The mutual repression observed between ERG and nuclear receptors lends some credibility to the hypothesis that ERG and nuclear receptors could physically interact. To evaluate whether functional interaction between ERa and ERG correlated with physical interaction, GST pull-down experiments were performed with GST fusion proteins containing full-length ERG and in vitro translated 35 S methionine-labeled fulllength ERa. These experiments failed to detect any specific retention of ERa when GST alone or GST-ERG fusion protein were used (data not shown) and were consistent with gel retardation assays, which showed that addition of ERa did not induce significant shift of the ERG-EBS complex (see above).
Next, we developed a series of mammalian two-hybrid assays to confirm that ERa and ERG do not engage direct protein-protein interaction in vivo. For this purpose, we used fusion protein containing full-length ERa along with the acidic activation domain of HSV VP16 protein. Full-length and mutant ERG sequences were produced as fusion with the yeast Gal4 DNAbinding domain (Gal4DBD). Interactions between ERa/ VP16 and the ERG/Gal4DBD fusions were assessed in the presence of estradiol by using the pG5-LUC reporter gene, which contains five copies of the Gal4 responsive element upstream of the luciferase gene. The activities generated were quantitated and compared to those produced by control interactions between Id/Gal4DBD and MyoD/VP16 fusion proteins. Cotransfections of ROS cells with ERa/VP16 and Gal4DBD fusion plasmids containing either wild-type ERG, ERGDDBD (lacking the ETS DNA-binding domain) or the ERGDBD, did not generate significant luciferase activities as compared with controls (data not shown). The same experiments were performed using ERbVP16 or RARa/VP16 in the presence of the corresponding ligand and we also failed to demonstrate any significant binding between ERG and these nuclear receptors. As a final control, we inversely produced proteins containing full-length ERG fused to the acidic activation domain of VP16 and proteins containing full-length ERa or ERb fused to the Gal4DBD. No significant activation was observed when compared to the control interaction between Id/Gal4DBD and MyoD/VP16 fusion proteins (data not shown). Along with gel retardation assays and GST pull-down experiments, these results argue against direct protein-protein interactions between ERG and nuclear receptors.
Carboxyterminal and aminoterminal transactivation domains of ERG are required for repression of ERa-dependent transcription To understand the mechanism by which ERG represses ERa activity and to know which structural domain of ERG mediates this effect, we examined the effect of wild-type and mutant ERG proteins on ERa activity in ROS cells cotransfected with the reporter plasmid ERE-LUC. Mutants described by Carre`re et al (1998) were chosen regarding ERG functional domains, namely the ETS DNA-binding domain (DBD) and the two aminoterminal and carboxyterminal transactivation domains (Figure 6a ) (Siddique et al., 1993; Carre`re et al., 1998) . The ERG mutant ERGp55 , which lacks the aminoterminal part of ERG including the aminoterminal transactivation domain (Figure 6a ), did not act as a repressor (Figure 6b ), suggesting that the ERG aminoterminal transactivation domain, which overlaps the conserved POINTED domain (Siddique et al., 1993; Carre`re et al., 1998) , is involved in the repression of ERa activity. Another aminoterminal ERG deletion mutant, ERGp55 307-479 , induced more marked repression than wild-type ERG. A central domain between amino acids 248 and 307 has been shown to inhibit the transactivation activity of the ERG protein (Carre`re et al., 1998) . To test whether the more effective repression of ERGp55 307-479 mutant results from a constitutive repressive conformation or from the deletion of the 248-307 domain, we studied the repressive activity of the mutant ERGp55 D249-308 lacking this inhibitory domain. This mutant behaved as a lessefficient repressor of ERa-dependent transcription than wild-type ERG (Figure 6 ). This suggests that the 249-308 domain may play a role in the repressive activity of ERG and that the more effective repression of ERGp55 307-479 mutant results from a constitutive repressive conformation. On the other hand, since the ERG DBD is thought to include the nuclear localization signal (Boulukos et al., 1989) , we did not directly test whether the mutant ERGp55 DDBD , which lacks the DBD, represses ERa activity but rather used a fusion protein containing ERGp55 DDBD fused to the yeast Gal4DBD. As shown in Figure 6 , this deletion mutant repressed as effectively as wild-type ERG. The ERG DBD is therefore unlikely to play a role in the repression of ERa-dependent transcription. Furthermore, the mutant ERGp55 DBD , which only retains the DBD of the wildtype ERG protein, did not act as a repressor. Finally, since the ERGp55 307-479 mutant acts as a repressor, we inferred that the carboxyterminal part of ERG was likely to be involved in the repression of ERa activity. The mutant ERGp55 , in which the carboxyterminal transactivation domain is deleted, did not repress ERa activity when cotransfected in ROS cells (Figure 6 ), suggesting that an intact carboxyterminal transactivation domain is required for ERG-mediated repression of ERa activity. Accordingly, mutant ERGp55 1-433 only lacking the carboxyterminal transactivation domain also failed to repress ERa-dependent transcription (Figure 6 ) suggesting that both transactivation domains (N-and C-term) are required to repress ERa effect.
AF-2 domains of ERa and ERR1 are required to repress ERG activity
To delineate the regions of ERa that are necessary to repress ERG activity, a series of ERa deletion mutants was cotransfected in ROS cells along with ERGsensitive Pye-LUC reporter plasmid and ERG expression plasmid. We mostly intended to determine whether transactivation domains of ERa could mediate repression of ERG-dependent transcription and first tested mutants lacking various portions of the aminoterminal part of ERa, where the AF-1 domain has been localized (Figure 7a) (Metzger et al., 1995) . The three receptor ) were as effective as wild-type ERa in repressing ERG activity in presence of estradiol (Figure 7b) , suggesting that the aminoterminal part of the receptor, and in particular the AF-1 domain is not necessary for repression. On the other hand, we tested four mutants bearing mutations in the carboxyterminal part. The first one only comprises the A, B and C domain, thus lacking the whole ligandbinding domain, and did not behave as a repressor, suggesting that the DNA-binding C domain was not sufficient to induce repression of ERG activity. The three other mutants chosen were ERa S554fs , ERa L540Q and ERa , which proved to exhibit specific functional particularities such as conserved estradiol binding, conserved DNA binding, reduced transactivation and strong dominant negative activity (Ince et al., 1993; Wrenn and Katzenellenbogen, 1993; Potthoff et al., 1996) . As shown in Figure 7b , mutant ERa
S554fs
, which includes a frame shift from amino acid 554, behaved as a hormone-dependent repressor as efficiently as the wildtype ERa. By contrast, ERa L540Q and ERa , which harbor point mutation of a conserved leucine in the AF-2 domain and deletion of the whole AF-2 domain respectively, only slightly repressed ERG-dependent transcription even in the presence of estradiol (Figure 7b ). The AF-2 domain of ERa appears therefore required for efficient repression of ERG-dependent transcription.
To determine whether these results could be reproduced with other nuclear receptors, we also used deletion mapping studies to identify regions in ERR that are required for repression. As expected, a mutant lacking the aminoterminal AF-1 domain (Vanacker et al., 1999) was as effective as wild-type ERR1 in repressing ERG activity. But a mutant lacking the carboxyterminal AF-2 domain (Vanacker et al., 1999) was unable to repress ERG-dependent transcription (Figure 8 ). Altogether, these experiments indicate that an intact carboxyterminal AF-2 domain is required to repress ERG activity by nuclear receptors.
CBP, SRC-1 and RIP 140 do not rescue ERa-repressed ERG-dependent transcription
Taken together, the symmetry of the transcriptional repression and the lack of interference with DNA binding, along with the lack of direct protein-protein interaction and the involvement of ERG and ERa transactivation domains, support a mechanism by which specific squelching of a common coactivator leads to the mutual negative cross-talk observed between ERG and ERa. We therefore aimed to identify the limiting coactivators. CBP as well as the highly related p300 protein are nuclear phosphoproteins that operate as transcriptional coactivators by bridging a very large number of DNA-bound transcription factors, including nuclear receptors and ER receptors, AP-1 complex or ETS factors, with basal transcription complex (Kamei et al., 1996; Kraus and Kadonaga, 1998; Yang et al., 1998; Jayaraman et al., 1999; Kobayashi et al., 2000) . CBP and p300 appeared in some assays to be limiting and quantitatively important for transcriptional factors (Kamei et al., 1996; Lee et al., 1996; Avantaggiati et al., 1997; Horvai et al., 1997; Fronsdal et al., 1998; Sheppard et al., 1998; Lopez et al., 1999; Luo and YuLee, 2000; Takahashi et al., 2000) . We therefore explored a potential role for CBP in the mediation of ERG and ERa mutual repression. In the transfection assay in which ERG inhibited ERa-induced activation, increased levels of CBP should restore ERa-dependent activation if competition for limiting quantities of CBP accounts for the inhibitory effect of ERG. However, we did not detect CBP influence on ERa-induced inhibition of ERG-dependent activation. We also tested the effect of CBP in the ERG-induced inhibition of ERadependent activation. Although CBP efficiently stimulated ERa activity, cotransfection of increasing amounts of CBP did not relieve this inhibition but rather slightly enhanced it (data not shown). These results therefore argue against the titration of CBP in the mutual repression of ERG and ERa.
In ERa, leucine 540 belongs to the hydrophobic consensus sequence, which is thought to interact directly with the p160 family of nuclear receptor coactivators (motif FFXEFF where F represents a hydrophobic amino acid such as leucine, X any amino acid, and E glutamic acid) (Glass and Rosenfeld, 2000) . As shown above, the ERa L540Q mutant did not repress ERG activity, suggesting that the integrity of this hydropho- Figure 1b Mutual repression between ERG and ER V Vlaeminck-Guillem et al bic consensus motif is mandatory to repress ERG activity. We therefore tested whether the limiting cofactor could be the SRC-1 coactivator. But cotransfection of increasing amounts of SRC-1 did not relieve the ERa-mediated repression of ERG-dependent transcription (not shown). Since SRC-1 was ineffective in enhancing ERG activity on Pye-LUC reporter, even in the absence of ERa (not shown), SRC-1 is unlikely to be titrated in the ERG and ERa interaction. Likewise, cotransfection experiments made RIP140 unlikely to mediate this cross-talk (not shown).
Discussion
Our results show that ERG can be a potent inhibitor of the ligand-activated ERa. We further demonstrated that ERa is able to block ERG-dependent transcription. Reciprocal inhibition is neither due to mutual interference of these proteins with each other's DNA-binding activity, nor to a direct protein-protein interaction, but most likely results from an interaction through common targets in the transcription machinery.
The present findings that ERG (and FLI1) and several nuclear receptors including ERa, ERb, ERR1, Tra1, TRb1, RARa and RXRa, engage in cross-talk broaden our view of previous experiments, taking them a little farther (Gauthier et al., 1993; Schneikert et al., 1996; Darby et al., 1997; Aurrekoetxea-Hernandez and Buetti, 2000; Dwivedi et al., 2000; Oettgen et al., 2000; Tolon et al., 2000; Mullick et al., 2001) and suggest that this interaction may actually occur regularly between the two families of transcription factors. Nuclear receptors involved in functional interaction with ETS factors belong to the family of receptors of both steroidal (GR, ER, AR) and nonsteroidal factors (TR, VDR, RAR, RXR) as well as to the orphan receptor subfamily (ERR1, RORa). All the effects described in these studies have furthermore been observed in several cell systems. Some of the previously described interactions between ETS factors and nuclear receptors are synergistic (Aurrekoetxea-Hernandez and Buetti, 2000; Dwivedi et al., 2000; Oettgen et al., 2000; Tolon et al., 2000; Mullick et al., 2001) . In these experiments, transcriptional synergism requires the binding of both ETS factors and nuclear receptors on adjacent specific DNA cognate elements within the target promoters and potentially direct protein-protein interactions.
Our experiments showed that not all nuclear receptors expression vectors gave rise to progressive inhibitions of ERG-mediated transactivation with increasing vector concentration. This observation may be significant of separate mechanisms occurring with different types of nuclear receptors. However, the mutual repressions observed in the present study show several common features. The mechanism by which ETS factors and nuclear receptors repress each other's activity is far more elusive. In most of the previous studies, the repression of ETS factor-mediated transcription by nuclear receptors is higher when the nuclear receptors are activated by a bound ligand (Gauthier et al., 1993; Darby et al., 1997; Schneikert et al., 1996) . In our experiments, whatever the nuclear factor, the repression of ERG-mediated transactivation was by far higher in the presence of the ligand. This suggests that the ligand-induced active conformation favors interaction with ETS factors. In fact, a GR mutant lacking the ligand-binding domain but having conserved an active constitutive conformation retained the ability to repress Spil/PU.1 activity (Gauthier et al., 1993) . Whether the conformational change unmasks an ETS factor-interacting domain or allows antagonistic interference with DNA binding or interaction with protein partners remains to be determined. However, we demonstrated, along with others (Gauthier et al., 1993; Darby et al., 1997) , that ETS factors and nuclear receptors antagonize each other's activity by a mechanism that does not require protein-DNA interaction or disruption of their DNA-binding activity. In the present study, ERG did not bind to ERaresponsive elements and did not prevent ERa-DNA complexes to form, but neither did ERa. Although direct evidence of protein-protein interaction has been reported between GR and VDR (Mullick et al., 2001) and between AR and ERM (Schneikert et al., 1996) or PDEF (Oettgen et al., 2000) , other efforts have been unsuccessful (Darby et al., 1997) . In the present study, several lines of evidence argue against a direct proteinprotein interaction between ERG and ERa: no ternary complex could be observed using gel retardation assays, GST pull-down experiments was unsuccessful, and two-hybrid assays failed to show any significant interaction. This does not definitely rule out the possibility of low affinity direct interaction between ETS factors and nuclear receptors, and results are not inconsistent with an indirect association through a bridging factor. Alternately, the two transcription factors might block or destabilize each other's interaction with a nuclear factor that facilitates transcription activity.
The delineation of the functional domains required for mutual repression of transactivation domains in both ERG and ERa also argue for reciprocal inhibition of interaction with a common coactivator. In the ERG protein, as well as in FLI1 and Spil/PU.1, the interactions are mediated by sequences located outside the ETS domain. These regions are poorly conserved among the ETS factors (Graves and Petersen, 1998; Laudet et al., 1999) . It is therefore likely that the repression activity against nuclear receptors will prove to occur only in members of ETS subsets. For instance, although Spil/PU.1 repressed ER, Ets2 had no effect (Gauthier et al., 1993) . Likewise, ETS1, ELF1 and GABPa did not repress GR activity whereas Fli1 did (Darby et al., 1997) . These discrepancies also suggest that the mutual transcriptional interferences described so far between ETS factors and nuclear receptors might result from mechanisms that differ with ETS factors. We found that the ERG-mediated repression of ERa activity depends on the aminoterminal transactivation domain, as observed with Fli1-mediated repression of RARa activity (Darby et al., 1997) , as well as on the carboxyterminal transactivation domain. The aminoterminal transactivation domain of ERG and FLI1 overlaps the conserved POINTED domain (Siddique et al., 1993; Carre`re et al., 1998) . Since this domain proved to be involved in dimerization properties in ERG and TEL proteins (Jousset et al., 1997; Carre`re et al., 1998) , one wonders whether this domain participates in direct protein-protein interactions. On the other hand, in ERa as well as in ERR1, deletion mapping studies showed that the AF-2 domain is required for full repression of ERG activity. This result is consistent with previous experiments showing that the carboxyterminal part of the RARa protein, associated with the DNAbinding domain, is required to repress the FLI1-dependent transcription (Darby et al., 1997) . Our results with orphan nuclear receptors also back the hypothesis according to which the AF-2 domain is involved in repressing ERG activity. RORa, which features an efficient AF-2 domain, represses ERG activity whereas REV-ERBa, which lacks an AF-2 domain, and COUP-TFII, in which AF-2 is not functional, does not repress ERG activity. It has been shown that nuclear receptor AF-2 mediates the direct protein-protein interactions with several partners. We postulated that titration of common cofactors may be involved in the mutual transcriptional interference observed between ERG and ERa.
Several lines of evidence suggest that competition for limiting coactivator proteins in the nucleus accounts for at least some aspects of mutual repression between transcription factors. Since CBP and p300 are highly related coactivators important for nuclear receptor activity, it has been suggested that they mediate the mutual transcription interference between the two families of transcription factors (Kamei et al., 1996) . Several other examples of CBP/p300 titration have been subsequently described (Lee et al., 1996; Avantaggiati et al., 1997; Horvai et al., 1997; Fronsdal et al., 1998; Sheppard et al., 1998; Lopez et al., 1999; Luo and YuLee, 2000; Takahashi et al., 2000) . CBP/p300 is limiting and quantitatively important in the action of ETS factors (Yang et al., 1998; Jayaraman et al., 1999) . ETS1 and ETS2 can engage in direct protein-protein interaction with two cysteine/histidine-rich regions of CBP/ p300 through their ETS DNA-binding domains and, to a lesser extent, through their aminoterminal part encompassing the conserved PNT domain (Yang et al., 1998; Jayaraman et al., 1999) . ERG protein also contains the PNT domain (Rao et al., 1987) and p300 has been shown to coactivate ERG on the synthetic promoter-reporter construct E18pal in which two palindromic ETS sites are placed upstream of a c-fos minimal promoter (Jayaraman et al., 1999) . On the rat stromelysin promoter, p300 does not cooperate with ERG either (Jayaraman et al., 1999) . Nevertheless, we failed to demonstrate any significant influence of excessively expressed CBP on the mutual repression of ERG and ERa, suggesting that CBP is not the limiting factor titrated by both transcriptional factors. The SRC-1 coactivator also mediates the mutual repression exerted by nuclear receptors (Lopez et al., 1999) , by nuclear receptors and AP-1 complex (Lee et al., 1998) , and by nuclear receptors and NFkB/Rel (Sheppard et al., 1998) . Although the integrity of the p160 coactivatorinteracting hydrophobic sequence of ERa is required for efficient repression of ERG activity, SRC-1 is unlikely to be the limiting factor titrated in the ERG and ERa cross-talk. The same can be said of the other ERa partner RIP140, which failed to rescue ERG and ERa activity.
Reciprocal inhibition between ERG and nuclear receptors provides an example of the potential crosstalk between the membrane and nuclear receptor signaling pathways to regulate gene transcription in response to extracellular stimuli. Such interactions might play relevant roles in controlling cell biology, by providing cells with a complex regulatory mechanism promoting cell growth or differentiation. The cross-talk between ERa and the ERG signal transduction pathway reported here might be relevant in tissues where both transcription factors are expressed -endothelial, urogenital and cartilaginous tissues (Dhordain et al., 1995; Vlaeminck-Guillem et al., 2000) . This type of cross-talk appears to be a generic mechanism shared by other ETS factors and a variety of nuclear receptors. It confers an intriguing functional variability to both families of transcription factors and extends their potential range of regulation. Several inherited endocrine disorders result from naturally occurring mutations in the genes encoding nuclear receptors. Active and inactive mutations induce hyper-responsiveness or resistance to the corresponding hormone, respectively. A constant and intriguing feature of these disorders is the great phenotypic variability, regarding the magnitude of clinical symptomatology. The influence of mutations on the nuclear receptor's ability to interact with ETS factors may partly account for this variability since they sometimes lie in the domain we found to be responsible for repression of ERG activity, the AF-2 domain. Conversely, ETS factors are known to mediate mitogenic signals and have been involved in several human malignancies including, for the ERG factor, myeloid leukemia, Ewing's sarcoma or uterine cervical carcinoma (Delattre et al., 1992; Shimizu et al., 1993; Zucman et al., 1993; Simpson et al., 1997) . The data reported here, combined with previous results on anti-AP-1 activity of nuclear receptors (Pfahl, 1993) , suggest that nuclear receptors may play a prominent role as antioncogenes. The inhibition of ETS factors by nuclear receptors might indeed serve as an important regulatory pathway to suppress inappropriate cellular proliferation initiated by ETS oncoproteins and could give another molecular rational for the use of hormones such as glucocorticoids and retinoic acid in some human malignancies. s ) supplemented with 10% fetal calf serum (FCS) and gentamycin (100 U/ml). When necessary (hormone tests), cells were grown for 48 h in phenol-red-free medium supplemented with charcoal-treated FCS. In this treated culture medium, hormone concentrations were minimized but small residual hormone activities were observed. For transfection experiments, cells were rinsed and incubated in 1 ml of OptiMEM (Life Technologies Inc. s ). A total of 1.5 Â 10 5 cells seeded in six-well plates were transfected with a mixture of DNAs (total amount 1 mg) using 4 ml Polyethylene imine (Euromedex s ). To incubate plates with the same total plasmid amounts, the DNA mixtures were completed as necessary with the corresponding empty vector. We used pSV2-Luc plasmid as positive control of transfection. In some experiments randomly chosen, Western blots were performed to check correlation between amounts of transfected plasmids and amounts of expressed proteins. When necessary, hormone was added to the culture medium after transfection as indicated. Cells were incubated for 48 h, harvested and disrupted in lysis buffer (Promega s ). The supernatant was assayed for luciferase and CAT activity using standard methods. Triplicate samples were performed in two or three experiments, and the values obtained were verified by normalization to the proteins content of each cell extract. For repression experiments on ERG-sensitive and ERa-sensitive promoters, results were normalized to the reporter activity obtained with the full-length ERG and ERa proteins, respectively.
Materials and methods
Cells
Plasmid constructions
The ERG-sensitive reporter plasmid Pye-LUC contains four copies of the artificial Py enhancer element (Pye), cloned upstream of the TK promoter and a luciferase reporter gene (Wasylyk et al., 1989; Carre`re et al., 1998) . This reporter plasmid was also sensitive to FLI1. The ERG-sensitive reporter plasmid (E74) 4 -LUC, kindly provided by Dr J-L Baert, contains four copies of E74 target sequence, cloned upstream of the TK promoter and a luciferase reporter gene. The nuclear receptor-responsive reporter plasmids include specific hormone responsive elements, cloned upstream the TK promoter and a luciferase or a CAT reporter gene. The ERa, ERb or ERR1-sensitive reporter plasmid ERE-LUC has been described in Vanacker et al. (1999) . We used the expression plasmids for human ERG (pSG5-ERGp55), human FLI1 (pSG5-FLI1), human ERa (pSG5-ERa), mouse ERb (pSG5-ERb), mouse ERR1 (pSG5-ERR1), human TRa1 (pSG5-TRa1), human TRb1 (pSG5-TRb1), mouse RARa (pSG5-RARa), mouse RXRa (pCMX-RXRa), human REV-ERBa (pSG5-REV-ERBa), RORa (pCMX-RORa). The pCMX-CBP expression plasmid was kindly provided by Dr D Monte´. The pSG5-COUP-TFII plasmid was constructed by subcloning a COUP-TFII sequence in the parental vector pMT2-COUP-TFII (Ladias and Karathanasis, 1991) . The expression plasmids for human SRC-1 (pSG5-SRC-1) and RIP140 (pBEF-Bos-RIP140) were kindly provided by Dr V Cavailles. The ERG deletion mutants have been described previously (Carre`re et al., 1998) . The ERa carboxyterminal mutants correspond to mutants S554fs, L540Q and ER1-530 described in (Ince et al., 1993) . The ERa aminoterminal mutants have been described in (Pettersson et al., 1997) . ERR1 deletions have been described elsewhere (Vanacker et al., 1999) .
In vitro protein synthesis and electrophoretic mobility shift assays
In vitro translated proteins (ERGp55, ERa) were generated with a rabbit reticulocyte in vitro transcription/translation system (TNT/Promega s ). EMSA were performed as described (Libermann and Baltimore, 1993) . Briefly, the DNA-binding reaction was performed at 41C for 30 min in 20 ml of DNA binding buffer containing 20 mM Tris, pH 7.5; 80 mM NaCl; 2 mM DTT; 0.1% Triton X-100; 5% glycerol and 5 mg/ml poly dIdC. As a probe, we used a double-stranded oligonucleotide corresponding to the ETS consensus binding site (EBS) 5 0 GATCTTCGAAACGGAAGTTCGAG 3 0 labeled with g-32 P-dATP at a concentration of 10 000 cpm per reaction. Each binding reaction mixture was adjusted to equal amounts of reticulocyte lysate by adding the appropriate amounts of unprogrammed lysate. Protein-DNA complexes were resolved by 5-10% polyacrylamide gel containing 2% glycerol in TBE buffer. Autoradiography was performed on dry gel. Hormone tests were performed by preincubating the in vitro translated proteins with estradiol when appropriate. To analyse protein-protein interactions, proteins were preincubated on ice for 15 min before the DNA-binding assays were performed.
Pull-down assays
For pull-down assays, in vitro translated proteins were labeled with 50 mCi 35 S-methionine/50 ml reticulocyte lysate. The translation products were visualized by SDS-PAGE and quantified by Phosphor Imager (Molecular Dynamics s ). The bacterial expression of GST constructs and the purification of GST fusion proteins were performed as previously described (Carre`re et al., 1998) . For pull-down assays, 50 ml of glutathione sepharose beads (Pharmacia s ) were incubated with 1 mg of either GST or GST-ERG fusion proteins in NETN (20 mM Tris HCl pH 8, 200 mM NaCl, 1 mM EDTA, 0.5% Nonidet NP40), for 1 h at 41C with gentle shaking. Beads were washed three times with incubation buffer (12 mM HEPES pH 7.9, 4 mM Tris-HCl pH 7.9, 50 mM NaCl, 10 mM KCl, 1 mM EDTA) and resuspended in 30 ml of a mixture containing 35 S-labelled protein expressed in reticulocyte lysate and incubation buffer. After 1 h at 41C, beads were washed six times with NETN and mixed with SDS-sample buffer. The bound proteins were analysed by SDS-PAGE followed by autoradiography.
Mammalian two-hybrid assays
The VP16-ERa, VP16-ERb and VP-16RARa fusion constructs were kindly provided by Dr D McDonnell (Chang et al., 1999) . cDNA encoding for ERG full-length protein as well as the ERG deletion mutants ERGDDBD and ERGDBD were cloned into the pSG5424plasmid, containing the GAL4DBD or into the pSG-FNV (Flag-NLS-VP16 activation domain). The ERa coding sequence was extracted from the VP16-ERa construct and cloned into the pSG5424 plasmid. The pG5LUC vector from the CheckMate mammalian two-hybrid kit (Promega s ) was used as a GAL4-responsible reporter plasmid. ROS cells were transfected as described above. The pSG5-b-galactosidase (b-gal) vector (50 ng) was cotransfected in each assay to correct for variations in transfection efficiency. The activities generated were compared to those produced by control interactions between Id/Gal4DBD and MyoD/VP16 fusion proteins (Promega s ). Results presented are the means of at least three independent transfections. fusion constructs, respectively. We also thank Drs J Coll and P Guillem for critical reading of the manuscript, and Dr JL Wemeau for constant encouragement. This work was supported by grants from CNRS, Institut Pasteur de Lille, Universite´de Lille II and Association pour la Recherche sur le Cancer.
